Skip to main content

Advertisement

Table 1 The catalog of drugs in the optimized personalized combinatorial therapies

From: Optimization of personalized therapies for anticancer treatment

  % of samples treated K f Markers Target
c 1 2 3 3 3 3 3
Embelin 0.7 5.9 31.5 2 13 lung: small_cell_carcinoma,TP53:wt XIAP
Nutlin-3a 4.1 8.0 24.5 2 11 TP53:wt,RB1:wt MDM2
Bicalutamide 1.3 3.9 21.4 2 11 ALK:wt,KRAS:0 Androgen receptor (ANDR)
XMD8-85 1.0 5.7 19.5 2 9 CDKN2A:wt,malignant_melanoma ERK5 (MK07)
Shikonin 1.7 1.7 11.8 1 2 TP53:wt unknown
NVP-BEZ235 0.6 - 8.0 2 4 PTEN:wt,EZH2:wt PI3K (Class 1) and mTORC1/2
CI-1040 1.8 3.8 7.6 2 6 malignant_melanoma,TP53:p.R273H MEK1/2
EHT 1864 1.1 3.5 7.1 1 2 lung: small_cell_carcinoma Rac GTPases
BMS-754807 - 4.1 7.0 2 14 neuroblastoma,KRAS:p.G12V IGF1R
PLX4720 0.8 3.5 6.9 2 13 BRAF:p.V600E,MSH2:wt BRAF
BX-795 0.7 5.7 6.3 2 14 glioma,KRAS:+ TBK1, PDK1, IKK, AURKB/C
AKT inhibitor VIII 2.4 5.6 6.3 2 9 lung: NSCLC: adenocarcinoma,EGFR:wt AKT1/2
AZD6482 3.8 6.2 6.3 1 2 glioma PI3Kb (P3C2B)
RDEA119 3.9 7.4 6.0 2 13 malignant_melanoma,BRCA1:0 MEK1/2
MS-275 4.9 5.9 5.9 2 6 lung: small_cell_carcinoma,RB1:wt HDAC
BI-D1870 0.7 1.7 5.3 2 14 CCND1:0,MYCN:0 RSK1/2/3/5, PLK1, AURKB
MG-132 1.4 - 5.2 1 2 glioma Proteasome
FH535 1.5 3.6 5.0 2 14 breast,CCND1:+ unknown
Docetaxel 2.8 1.3 4.6 2 9 upper_aerodigestive_tract,EGFR:wt Microtubules
CGP-60474 - 2.8 4.3 1 2 CDKN2a(p14):p.? CDK1/2/5/7/9
AS601245 1.7 2.5 4.2 2 7 ovary,osteosarcoma JNK
NVP-TAE684 1.5 3.8 4.2 1 1 APC:wt,stomach ALK
Epothilone B 1.3 1.4 4.1 2 7 PIK3CA:p.E545K,TP53:p.R248W Microtubules
Camptothecin 2.9 3.8 4.1 2 7 AML,lymphoblastic T cell leukaemia TOP1
Vorinostat 4.1 5.7 4.1 1 2 MYCN:+ HDAC inhibitor Class I, IIa, IIb, IV
A-443654 1.4 3.6 4.1 1 1 SMAD4:wt AKT1/2/3
PD-0325901 1.1 2.1 3.9 2 11 large_intestine,VHL:0 MEK1/2
RO-3306 1.5 3.2 3.9 2 11 cervix,MYCL1:0 CDK1
17-AAG 2.2 2.2 3.8 2 6 STK11:wt,MET:0 HSP90
S-Trityl-L-cysteine 1.1 3.5 3.8 1 1 FBXW7:wt KIF11
ZM-447439 0.1 1.3 3.6 2 7 lung: NSCLC: large cell,RB1:- AURKB
Vinblastine 1.4 2.2 3.2 2 13 upper_aerodigestive_tract,IDH1:0 Microtubules
Paclitaxel 0.1 2.5 3.2 2 11 oesophagus,TSC1:wt Microtubules
AICAR 0.6 1.7 2.9 1 1 KDM6A:wt AMPK agonist
BIBW2992 1.4 2.2 2.9 1 1 ERBB2:0 EGFR, ERBB2
JNK-9L - - 2.7 1 2 AML JNK
BAY 61-3606 1.0 2.1 2.7 1 2 Ewings sarcoma SYK
AMG-706 - - 2.7 1 2 Ewings sarcoma VEGFR, RET, c-KIT, PDGFR
AZ628 - 2.2 2.5 2 9 KRAS:p.G12D,FGFR3:0 BRAF
BMS-536924 - 1.1 2.5 2 7 KRAS:+,MDM2:+ IGF1R
JW-7-52-1 1.1 1.7 2.5 1 2 stomach MTOR
Elesclomol 1.0 3.5 2.4 2 8 bladder,TSC1:wt HSP70
Pyrimethamine 0.8 3.5 2.4 1 2 pancreas Dihydrofolate reductase (DHFR)
KIN001-135 0.3 0.7 2.2 1 1 MET:+ IKKE
Dasatinib - - 2.0 2 13 Renal cell carcinoma,NRAS:0 ABL, SRC, KIT, PDGFR
ABT-888 1.5 2.5 1.7 2 11 lymphoid_neoplasm other,CDK4:0 PARP1/2
BI-2536 2.9 3.1 1.7 2 2 CDKN2A:p.0?,MYC:0 PLK1/2/3
IPA-3 - - 1.7 1 2 B cell lymphoma PAK
WO2009093972 1.5 2.0 1.7 1 2 soft tissue other PI3Kb
Methotrexate 1.7 4.2 1.5 2 8 lymphoblastic leukemia,GNAS:wt Dihydrofolate reductase (DHFR)
Roscovitine 0.1 3.1 1.5 1 2 Burkitt lymphoma CDKs
FTI-277 1.4 1.4 1.5 1 2 thyroid Farnesyl transferase (FNTA)
PAC-1 1.5 1.5 1.5 1 2 Burkitt lymphoma CASP3 activator
CCT018159 1.3 3.5 1.4 2 14 osteosarcoma,PTEN:0 HSP90
PF-4708671 0.7 0.8 1.4 2 13 Myeloma,BRCA1:wt p70 S6KA
TW 37 0.8 1.1 1.4 2 6 MLH1:wt,APC:0 BCL-2, BCL-XL
MK-2206 1.3 1.4 1.4 1 2 endometrium AKT1/2
JNK Inhibitor VIII - - 0.3 1 2 AML JNK
Obatoclax Mesylate - - 0.1 2 2 RB1:-,CDK6:+ BCL-2, BCL-XL, MCL-1
  1. Drugs used for the treatment of at least one sample for maximum combination size c=3 and pharmacokinetic variations parameter σ=1. For each drug we report the drug-name and the percentage of samples treated with that drug (%). In the cases where the drugs were also included in the c=2 and 3 catalogs, the percentage of samples treated are reported as well. For the maximum combination size c=3 we also report the number of assigned markers K j , the assigned drug-to-sample protocol f j , the assigned markers, and the drug target.